Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transporters

Molecular Pharmacology

Volumn 79, Issue 3, 2011, Pages 520-532

  Guptaroy, Bipasha ^a   Fraser, Rheaclare ^a   Desai, Aalisha ^a   Zhang, Minjia ^a   Gnegy, Margaret E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ALANINE; ASPARTIC ACID; BENZATROPINE; COCAINE; DOPAMINE TRANSPORTER; MEMBRANE PROTEIN; NORADRENALIN TRANSPORTER; THREONINE; TRANSMEMBRANE DOMAIN 1; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATION; DRUG BINDING SITE; LIGAND BINDING; LOW TEMPERATURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS;

AMPHETAMINE; BENZTROPINE; BINDING SITES; BIOTINYLATION; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; MUTAGENESIS, SITE-DIRECTED; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PHARMACOKINETICS; PROTEIN CONFORMATION;

EID: 79951978579     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.069039     Document Type: Article

References (47)

1. Amara SG and Kuhar MJ (1993) Neurotransmitter transporters: recent progress. Annu Rev Neurosci 16:73-93. (Pubitemid 23074001)
2. -)-coupled gamma-aminobutyric acid transporter from rat brain, impairs net flux but not exchange. J Biol Chem 275:34106-34113.
3. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, Newman AH, Javitch JA, Weinstein H, Gether U, et al. (2008) The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11:780-789.
4. Blakely RD and Bauman AL (2000) Biogenic amine transporters: regulation in flux. Curr Opin Neurobiol 10:328-336. (Pubitemid 30389299)
5. Bonnet JJ, Benmansour S, Costentin J, Parker EM, and Cubeddu LX (1990) Thermodynamic analyses of the binding of substrates and uptake inhibitors on the neuronal carrier of dopamine labeled with [3H]GBR 12783 or [3H]mazindol. J Pharmacol Exp Ther 253:1206-1214. (Pubitemid 20209384)
6. Chen N and Justice JB, Jr. (1998) Cocaine acts as an apparent competitive inhibitor at the outward-facing conformation of the human norepinephrine transporter: kinetic analysis of inward and outward transport. J Neurosci 18:10257-10268. (Pubitemid 29016545)
7. Chen N and Reith ME (2000) Structure and function of the dopamine transporter. Eur J Pharmacol 405:329-339.
8. Chen N and Reith ME (2007) Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells. J Neurochem 101:377-388. (Pubitemid 46525278)
9. Chen N, Rickey J, Berfield JL, and Reith ME (2004a) Aspartate 345 of the dopamine transporter is critical for conformational changes in substrate translocation and cocaine binding. J Biol Chem 279:5508-5519. (Pubitemid 38220576)
10. Chen N, Vaughan RA, and Reith ME (2001) The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by sitedirected mutagenesis. J Neurochem 77:1116-1127. (Pubitemid 32467066)
11. Chen N, Zhen J, and Reith ME (2004b) Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine. J Neurochem 89:853-864. (Pubitemid 38684733)
12. Danek Burgess KS and Justice JB, Jr. (1999) Effects of serine mutations in transmembrane domain 7 of the human norepinephrine transporter on substrate binding and transport. J Neurochem 73:656-664. (Pubitemid 29339839)
13. Distelmaier F, Wiedemann P, Brüss M, and Bönisch H (2004) Functional importance of the C-terminus of the human norepinephrine transporter. J Neurochem 91:537-546. (Pubitemid 39431149)
14. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, and Janowsky A (1999) Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 289:877-885. (Pubitemid 29191245)
15. Giros B and Caron MG (1993) Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14:43-49. (Pubitemid 23049339)
16. Gu H, Wall SC, and Rudnick G (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269:7124-7130. (Pubitemid 24217896)
17. Guptaroy B, Zhang M, Bowton E, Binda F, Shi L, Weinstein H, Galli A, Javitch JA, Neubig RR, and Gnegy ME (2009) A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation. Mol Pharmacol 75:514-524.
18. Han DD and Gu HH (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6:6.
19. Henry LK, Meiler J, and Blakely RD (2007) Bound to be different: neurotransmitter transporters meet their bacterial cousins. Mol Interv 7:306-309.
20. Indarte M, Madura JD, and Surratt CK (2008) Dopamine transporter comparative molecular modeling and binding site prediction using the LeuT(Aa) leucine transporter as a template. Proteins 70:1033-1046. (Pubitemid 351161959)
21. Johnson LA, Furman CA, Zhang M, Guptaroy B, and Gnegy ME (2005) Rapid delivery of the dopamine transporter to the plasmalemmal membrane upon amphetamine stimulation. Neuropharmacology 49:750-758. (Pubitemid 41483881)
22. Kantor L, Hewlett GH, Park YH, Richardson-Burns SM, Mellon MJ, and Gnegy ME (2001) Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells. J Pharmacol Exp Ther 297:1016-1024. (Pubitemid 32472499)
23. Kniazeff J, Shi L, Loland CJ, Javitch JA, Weinstein H, and Gether U (2008) An intracellular interaction network regulates conformational transitions in the dopamine transporter. J Biol Chem 283:17691-17701.
24. Liang YJ, Zhen J, Chen N, and Reith ME (2009) Interaction of catechol and noncatechol substrates with externally or internally facing dopamine transporters. J Neurochem 109:981-994.
25. Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, Sitte HH, Newman AH, Katz JL, and Gether U (2008) Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73:813-823. (Pubitemid 351397886)
26. Loland CJ, Grånäs C, Javitch JA, and Gether U (2004) Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding. J Biol Chem 279:3228-3238. (Pubitemid 38140556)
27. 2+ switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle. Proc Natl Acad Sci USA 99:1683-1688.
28. Meinild AK, Sitte HH, and Gether U (2004) Zinc potentiates an uncoupled anion conductance associated with the dopamine transporter. J Biol Chem 279:49671-49679. (Pubitemid 39577770)
29. Mortensen OV and Amara SG (2006) Gain of function mutants reveal sites important for the interaction of the atypical inhibitors benztropine and bupropion with monoamine transporters. J Neurochem 98:1531-1540. (Pubitemid 44200443)
30. Norregaard L, Frederiksen D, Nielsen EO, and Gether U (1998) Delineation of an endogenous zinc-binding site in the human dopamine transporter. EMBO J 17: 4266-4273. (Pubitemid 28362617)
31. Norregaard L and Gether U (2001) The monoamine neurotransmitter transporters: structure, conformational changes and molecular gating. Curr Opin Drug Discov Devel 4:591-601. (Pubitemid 32904856)
32. Owens MJ, Morgan WN, Plott SJ, and Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305-1322. (Pubitemid 28016506)
33. Ravna AW, Sylte I, and Dahl SG (2009) Structure and localisation of drug binding sites on neurotransmitter transporters. J Mol Model 15:1155-1164.
34. Reith ME, Wang LC, and Dutta AK (2005) Pharmacological profile of radioligand binding to the norepinephrine transporter: instances of poor indication of functional activity. J Neurosci Methods 143:87-94. (Pubitemid 40348792)
35. Rudnick G (1997) Mechanism of biogenic amine neurotransmitter transporters, in Neurotransmitter Transporetrs: Structure, Function and Regulation (Reith ME ed), New Jersey.
36. Schmitt KC, Zhen J, Kharkar P, Mishra M, Chen N, Dutta AK, and Reith ME (2008) Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wildtype and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties. J Neurochem 107:928-940.
37. + and substrate is triggered by substrate in a second binding site. Mol Cell 30:667-677.
38. Singh SK (2008) LeuT: a prokaryotic stepping stone on the way to a eukaryotic neurotransmitter transporter structure. Channels (Austin) 2:380-389.
39. Singh SK, Yamashita A, and Gouaux E (2007) Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448:952-956. (Pubitemid 47312772)
40. Sucic S, Dallinger S, Zdrazil B, Weissensteiner R, Jørgensen TN, Holy M, Kudlacek O, Seidel S, Cha JH, Gether U, et al. (2010) The N terminus of monoamine transporters is a lever required for the action of amphetamines. J Biol Chem 285:10924-10938.
41. Torres GE, Gainetdinov RR, and Caron MG (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4:13-25. (Pubitemid 37271085)
42. Ukairo OT, Bondi CD, Newman AH, Kulkarni SS, Kozikowski AP, Pan S, and Surratt CK (2005) Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther 314:575-583. (Pubitemid 41051016)
43. Ukairo OT, Ramanujapuram S, and Surratt CK (2007) Fluctuation of the dopamine uptake inhibition potency of cocaine, but not amphetamine, at mammalian cells expressing the dopamine transporter. Brain Res 1131:68-76. (Pubitemid 46070178)
44. Wang W, Sonders MS, Ukairo OT, Scott H, Kloetzel MK, and Surratt CK (2003) Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter. Mol Pharmacol 64:430-439. (Pubitemid 36910007)
45. --dependent neurotransmitter transporters. Nature 437:215-223.
46. Zhao Y, Terry D, Shi L, Weinstein H, Blanchard SC, and Javitch JA (2010) Singlemolecule dynamics of gating in a neurotransmitter transporter homologue. Nature 465:188-193.
47. Zhou Z, Zhen J, Karpowich NK, Goetz RM, Law CJ, Reith ME, and Wang DN (2007) LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317:1390-1393. (Pubitemid 47417479)